Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 2/20 | 0.80 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | DAO | P14920 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | DDO | Q99489 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyrrole SCHEMBL27718192 | 1.00 | AOC3 (0.80) | AOC3LOXL2ALDH1A1KDM4EGAA | |
| SCHEMBL37667 | 0.89 | AOC3 (1.00) | AOC3LOXL2ALDH1A1KDM4EGAA | |
| SCHEMBL29363162 | 0.89 | AOC3 (1.00) | AOC3LOXL2ALDH1A1KDM4EGAA | |
| Hydrochloric Acid SCHEMBL28968677 | 0.87 | AOC3 (1.00) | AOC3LOXL2ALDH1A1KDM4EGAA | |
| Iodide SCHEMBL2316310 | 0.87 | AOC3 (0.95) | AOC3LOXL2ALDH1A1KDM4EGAA | |
| Hydrochloric Acid SCHEMBL5435898 | 0.87 | AOC3 (1.00) | AOC3LOXL2ALDH1A1KDM4EGAA | |
| SCHEMBL28494735 | 0.80 | AOC3 (0.80) | AOC3LOXL2ALDH1A1KDM4EGAA | |
| Urea SCHEMBL28162531 | 0.80 | AOC3 (0.80) | AOC3LOXL2ALDH1A1KDM4EGAA | |
| SCHEMBL28124326 | 0.78 | AOC3 (0.77) | AOC3LOXL2ALDH1A1KDM4EGAA | |
| Propionic Acid SCHEMBL27836593 | 0.77 | AOC3 (0.67) | AOC3LOXL2ALDH1A1KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024046355-A1 | USE OF COMPOSITION INCLUDING MESENCHYMAL STEM CELLS FOR ALLEVIATING MYELOFIBROSIS | MEDICAL AND PHARMACEUTICAL INDUSTRY TECHNOLOGY AND DEVELOPMENT CENTER (CN) | 2024-03-07 | — | — | WO | claimed |
| CN-110381963-A | It is related to the immunotherapy method and composition of tryptophan metabolic pathway regulator | 朱诺治疗学股份有限公司 | 2019-10-25 | — | — | CN | claimed |
| US-20240207411-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | SEAPORT THERAPEUTICS, INC. | 2024-06-27 | — | — | US | disclosed |
| WO-2024046355-A1 | USE OF COMPOSITION INCLUDING MESENCHYMAL STEM CELLS FOR ALLEVIATING MYELOFIBROSIS | MEDICAL AND PHARMACEUTICAL INDUSTRY TECHNOLOGY AND DEVELOPMENT CENTER (CN) | 2024-03-07 | — | — | WO | disclosed |
| US-11883497-B2 | Lymphatic system-directing lipid prodrugs | PURETECH LYT, INC. (US) | 2024-01-30 | — | — | US | disclosed |
| US-20220001015-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | SEAPORT THERAPEUTICS, INC. | 2022-01-06 | — | — | US | disclosed |
| US-11180815-B2 | Methods for treating colorectal cancer using prognostic genetic markers | PACIFIC EDGE LIMITED (NZ) | 2021-11-23 | — | — | US | disclosed |
| US-10738361-B2 | Methods of predicting clinical course and treating multiple sclerosis | TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD. (IL) | 2020-08-11 | — | — | US | disclosed |
| EP-3675838-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | Puretecch LYT, Inc. (US) | 2020-07-08 | — | — | EP | disclosed |
| US-20200140955-A1 | Methods for Treating Colorectal Cancer Using Prognostic Genetic Markers | PACIFIC EDGE LIMITED (NZ) | 2020-05-07 | — | — | US | disclosed |
| US-20190353643-A1 | Method For Sorting Highly Effective Stem Cells For Treating Immune Disorder | CELLNLIFE INC. (KR) | 2019-11-21 | — | — | US | disclosed |
| US-20090265815-A1 | Sequence-determined DNA fragments and corresponding polypeptides encoded therapy | ALEXANDROV NICKOLAI | 2009-10-22 | — | — | US | disclosed |
| US-20090181384-A1 | Prognosis prediction for colorectal cancer | PACIFIC EDGE BIOTECHNOLOGY LIMITED (NZ) | 2009-07-16 | — | — | US | disclosed |
| CN-101365802-A | Method for detecting cancer | BIOMERIEUX SA (FR) | 2009-02-11 | — | — | CN | disclosed |
| US-20070214517-A1 | Sequence-determined DNA fragments and corresponding polypeptides encoded thereby | CERES, INC. (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070111210-A1 | Biomarkers for graft rejection | BIGAUD MARC | 2007-05-17 | — | — | US | disclosed |
| US-20060150283-A1 | Sequence-determined DNA fragments and corresponding polypeptides encoded thereby | ALEXANDROV NICKOLAI | 2006-07-06 | — | — | US | disclosed |
| US-20060048240-A1 | Sequence-determined DNA fragments and corresponding polypeptides encoded thereby | ALEXANDROV NICKOLAI | 2006-03-02 | — | — | US | disclosed |
| US-20050118665-A1 | Methods for conducting assays for enzyme activity on protein microarrays | PROTOMETRIX, INC. | 2005-06-02 | — | — | US | disclosed |
| CN-1268161-A | Cleaning composition containing specific oxygenase | PROCTER & GAMBLE (US) | 2000-09-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220001015-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | LIPA, MALT1, SGMS1 | AOC3 2489/4885LOXL2 371/4885ALDH1A1 1179/4885 |
| US-20070214517-A1 | Sequence-determined DNA fragments and corresponding polypeptides encoded thereby | RNGTT, CPSF1, CPSF6 | AOC3 4255/4885LOXL2 4608/4885ALDH1A1 4769/4885 |
| US-11883497-B2 | Lymphatic system-directing lipid prodrugs | LIPA, MALT1, SGMS1 | AOC3 2489/4885LOXL2 371/4885ALDH1A1 1179/4885 |
| US-20240207411-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | LIPA, MALT1, SGMS1 | AOC3 2489/4885LOXL2 371/4885ALDH1A1 1179/4885 |
| US-20060048240-A1 | Sequence-determined DNA fragments and corresponding polypeptides encoded thereby | RNGTT, CPSF1, CPSF6 | AOC3 4255/4885LOXL2 4608/4885ALDH1A1 4769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.